In recent years, methylation of RNA has attracted much attention due to its important role in post-transcriptional regulation of genes. Among them, the m6A modification of RNA is the highest methylation modification except for the 5′cap structure in mRNA. m6A related enzymes are divided into three categories:RNA methyltransferases, RNA demethylases and m6A binding proteins, which play roles in catalytic methylation modification, removal of methylation modification and identification of the methylation site of N6-adenosine, respectively. Then they can help participate in the downstream gene translation, mRNA degradation, control the speed of the RNA nuclear export, and so on. Among these enzymes, methyltransferase-like 3 (METTL3), as the core component of RNA methylation transferases, plays a role in regulating the overall m6A modification of cellular RNA. Cardiovascular diseases are a kind of diseases greatly affected by environmental factors, whereas the latter could affect the occurrence and development through epigenetic related mechanism. Therefore, epigenetics has become a hot issue in the study of cardiovascular disease. The purpose of this review is to briefly summarize the research work related to METTL3 in cardiovascular diseases, which is expected to help the subsequent scientific research and clinical workers to understand the mechanism of m6A in cardiovascular disease development.